Program
rezvilutamide
Also written as “SHR3680”, “Rezvilutamide Tablets” and “SHR3680 tablets”.
Its studies are mostly in Prostatic Neoplasms, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Apr 27, 201813 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 133 open or running | phase 3since Apr 27, 2018 | Feb 17, 2016 | Mar 2027phase 3 · NCT07241416 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 17, 2016First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT02691975 · 197 enrolled · China
- Apr 19, 2016Phase 1 study in NeoplasmsNCT02747342 · 33 enrolled · Australia
- Apr 27, 2018Phase 3 study in Prostatic NeoplasmsNCT03520478 · 654 enrolled · Bulgaria, China, Czechia and more
- Sep 23, 2019Phase 2 study in Prostatic NeoplasmsNCT04102124 · 20 enrolled · China
- Oct 22, 2020Phase 2 study in Prostate Cancer MetastaticNCT04603833 · 150 enrolled · China
- Nov 3, 20204 phase 1 studiesNCT04621669, NCT04631549, NCT04676035 and 1 more
- May 6, 2021Phase 1 study in Healthy Male SubjectsNCT04903158 · 48 enrolled · China
- Aug 9, 2021Phase 3 study in Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyNCT05009290 · 391 enrolled · China
- Oct 12, 2022Phase 1 study in Castration-Resistant Prostate CancerNCT05607693 · 52 planned · China
- Nov 17, 2025Phase 3 study in Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT07241416 · 206 planned · China
Ahead
- Mar 2027Primary completion: phase 3 study in Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT07241416
TargetBeta
AR →read by rule
“An orally bioavailable androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07241416Metastatic Hormone-sensitive Prostate Cancer (mHSPC) · China | 3 | Recruiting | Mar 2027 | 206 |
| NCT05607693Castration-Resistant Prostate Cancer · China | 1 | Recruiting | Nov 5, 2024 | 52 |
| NCT05009290Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy · China | 3 | Terminated | Sep 6, 2024 | 391 |
| NCT04903158Healthy Male Subjects · China | 1 | UNKNOWN | Mar 15, 2021 | 48 |
| NCT04676035Prostate Cancer Patients · China | 1 | Completed | Jan 26, 2022 | 18 |
| NCT04664725Prostate Cancer Patients · China | 1 | UNKNOWN | Jan 2021 | 18 |
| NCT04631549Hepatic Impairment · China | 1 | UNKNOWN | Jul 2023 | 24 |
| NCT04621669Drug-drug Interaction,SHR3680 · China | 1 | Completed | Sep 8, 2021 | 36 |
| NCT04603833Prostate Cancer Metastatic · China | 2 | UNKNOWN | Oct 1, 2022 | 150 |
| NCT04102124Prostatic Neoplasms · China | 2 | Terminated | Aug 31, 2021 | 20 |
| NCT03520478Prostatic Neoplasms · Bulgaria, China, Czechia and more | 3 | Active, not recruiting | Apr 30, 2023 | 654 |
| NCT02747342Neoplasms · Australia | 1 | Completed | Jun 28, 2019 | 33 |
| NCT02691975Prostatic Neoplasms · China | 2 | UNKNOWN | Dec 1, 2020 | 197 |
How it is read
Names in the registry
- “SHR3680”, 6 entries
- “Rezvilutamide Tablets”, 1 entry
- “SHR3680 tablets”, 1 entry
- “Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680”, 1 entry
- “test SHR3680 tablets”, 1 entry
Codes read as this program: SHR3680.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.